Share this
Zai Lab Enters License and Collaboration Agreement with Blueprint Medicines
I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment
CardioKinetix Completes $50 Million Financing
Adamas Pharmaceuticals Initial Public Offering
Ascendis Pharma closes $124 million IPO
Nexvet Biopharma Closes Initial Public Offering
Cour and Takeda Partner to Treat Celiac Disease
Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan
Avidity Biosciences Licensing and Research Collaboration with Eli Lilly
Otsuka $825 Million Collaboration Agreement to Develop Alzheimer's Drug
MyoKardia Collaboration with Sanofi
Portola Pharmaceuticals $140 Million IPO
Rigel Pharmaceuticals License and Supply Agreement with Kissei Pharmaceutical Valued up to $180 Million
Turnstone Biologics License Agreement with AbbVie
Vivo Capital in its Licensing Agreements with Ascendis Pharma
Xyphos Biosciences in its Research Collaboration and License Agreement with Parker Institute for Cancer Immunotherapy
Portola Agrees to Sell to Alexion for $1.41 Billion
Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech
Zai Lab Product Commercialization Collaboration with Regeneron
Vaxcyte - $288 Million IPO
Genesis MedTech Acquires Drug Device Asset From TriReme Medical
Goldfinch Bio Announces Strategic Collaboration with Gilead
Singapore’s Engine Biosciences Raises $43 Million to Decipher Genetic Codes for New Medicines
Lulu’s – $92 Million IPO
Fate Therapeutics Expansion of Collaboration with ONO Pharmaceutical